{"id":33480,"date":"2025-05-15T12:52:52","date_gmt":"2025-05-15T04:52:52","guid":{"rendered":"https:\/\/flcube.com\/?p=33480"},"modified":"2025-05-15T12:52:54","modified_gmt":"2025-05-15T04:52:54","slug":"abbvie-pays-335-million-upfront-to-adarx-for-next-gen-sirna-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33480","title":{"rendered":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics"},"content":{"rendered":"\n<p>US-based pharma giant AbbVie (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE: ABBV<\/a>) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.<\/p>\n\n\n\n<p><strong>Combining Expertise<\/strong><br>ADARx brings its siRNA technology and RNA discovery expertise to the table, while AbbVie\u2019s work in antibody engineering, antibody-drug conjugates and tissue delivery approaches will complement ADARx\u2019s discovery efforts. The deal is intended to accelerate siRNA as a potential new therapeutic modality alongside AbbVie&#8217;s other established approaches.<\/p>\n\n\n\n<p><strong>The Promise of siRNA<\/strong><br>According to Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, siRNA is a \u201cpromising genetic medicine approach for silencing disease-causing genes.\u201d Sedgwick notes, however, that obstacles still remain in \u201ctargeting and delivering siRNA effectively.\u201d siRNA works by preventing the production of disease-causing proteins by targeting the protein\u2019s respective messenger RNA.<\/p>\n\n\n\n<p><strong>ADARx&#8217;s Perspective<\/strong><br>According to ADARx CEO and co-founder Zhen Li, Ph.D., AbbVie is the \u201cideal strategic partner\u201d due to its R&amp;D capabilities and global commercial reach. Together, the two companies aim to unlock \u201ctremendous clinical and commercial potential across multiple disease areas.\u201d<\/p>\n\n\n\n<p><strong>ADARx&#8217;s Pipeline<\/strong><br>Outside of this collaboration, ADARx has a pipeline of wholly owned clinical and preclinical siRNA-based candidates targeting the liver, central nervous system and body fat. These span potential indications such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, obesity and neurodegeneration. ADX-324, the company\u2019s most advanced candidate, is set for a phase 3 trial in hereditary angioedema.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33482,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[234,4074,853],"class_list":["post-33480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-abbvie","tag-adarx-pharmaceuticals","tag-nyse-abbv"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33480\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics\" \/>\n<meta property=\"og:description\" content=\"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33480\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-15T04:52:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-15T04:52:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics\",\"datePublished\":\"2025-05-15T04:52:52+00:00\",\"dateModified\":\"2025-05-15T04:52:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1504.webp\",\"keywords\":[\"AbbVie\",\"ADARx Pharmaceuticals\",\"NYSE: ABBV\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33480#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33480\",\"name\":\"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1504.webp\",\"datePublished\":\"2025-05-15T04:52:52+00:00\",\"dateModified\":\"2025-05-15T04:52:54+00:00\",\"description\":\"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33480\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1504.webp\",\"width\":1080,\"height\":608,\"caption\":\"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33480#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33480","og_locale":"en_US","og_type":"article","og_title":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics","og_description":"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.","og_url":"https:\/\/flcube.com\/?p=33480","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-15T04:52:52+00:00","article_modified_time":"2025-05-15T04:52:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33480#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33480"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics","datePublished":"2025-05-15T04:52:52+00:00","dateModified":"2025-05-15T04:52:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33480"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33480#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","keywords":["AbbVie","ADARx Pharmaceuticals","NYSE: ABBV"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33480#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33480","url":"https:\/\/flcube.com\/?p=33480","name":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33480#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33480#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","datePublished":"2025-05-15T04:52:52+00:00","dateModified":"2025-05-15T04:52:54+00:00","description":"US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals, paying $335 million upfront to secure options on next-generation small interfering RNA (siRNA) therapeutics across several disease areas. The agreement covers neuroscience, immunology and oncology and presents ADARx with the opportunity to receive \u201cseveral billion dollars\u201d in additional option-related fees and milestone payments, plus royalties, according to a May 14 release.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33480#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33480"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33480#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","width":1080,"height":608,"caption":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33480#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33480"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33480\/revisions"}],"predecessor-version":[{"id":33483,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33480\/revisions\/33483"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33482"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}